Assetmark Inc. Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Assetmark Inc. lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,771 shares of the biopharmaceutical company's stock after purchasing an additional 9,612 shares during the quarter. Assetmark Inc. owned 0.08% of Halozyme Therapeutics worth $4,913,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 173.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock worth $93,000 after buying an additional 1,028 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in Halozyme Therapeutics by 38.4% in the third quarter. Janney Montgomery Scott LLC now owns 36,020 shares of the biopharmaceutical company's stock valued at $2,062,000 after acquiring an additional 9,995 shares during the last quarter. QRG Capital Management Inc. bought a new position in Halozyme Therapeutics in the third quarter valued at $245,000. Portside Wealth Group LLC raised its position in Halozyme Therapeutics by 132.1% during the third quarter. Portside Wealth Group LLC now owns 9,123 shares of the biopharmaceutical company's stock valued at $522,000 after purchasing an additional 5,192 shares in the last quarter. Finally, Verdence Capital Advisors LLC lifted its stake in Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock worth $757,000 after purchasing an additional 252 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Remove Ads

Halozyme Therapeutics Trading Down 0.9 %

HALO traded down $0.53 during trading on Wednesday, hitting $60.92. 992,575 shares of the stock traded hands, compared to its average volume of 1,313,101. The firm has a market capitalization of $7.50 billion, a P/E ratio of 17.76, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a 50-day moving average of $56.24 and a 200 day moving average of $54.67.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now owns 33,611 shares in the company, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,697 shares of company stock valued at $1,754,451. Company insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Benchmark reaffirmed a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.